Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Hematologic Malignancy Reports
Erschienen in: Current Hematologic Malignancy Reports 6/2018

22.10.2018 | T-Cell and Other Lymphoproliferative Malignancies (J Zain, Section Editor)

Breast Implant-Associated Anaplastic Large Cell Lymphoma

verfasst von: P. Rastogi, A. K. Deva, H. Miles Prince

Erschienen in: Current Hematologic Malignancy Reports | Ausgabe 6/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is a recently recognised malignancy of T lymphocytes exclusively associated with textured breast implants. This review aims to evaluate existing theories regarding the epidemiology, pathogenesis, clinical evaluation and management of the disease.

Recent Findings

The true incidence of BIA-ALCL is difficult to define. Prevailing pathogenic theories recognise the interplay between textured implants, Gram-negative bacteria, host genetics (e.g. JAK/STAT, p53) and time. Patients typically present with a delayed seroma and less commonly with a capsular mass or systemic disease at an average of 8–10 years after implantation. BIA-ALCL staging has evolved from a “liquid tumour” model to a “solid tumour” classification. For localised disease, surgery involving complete capsulectomy and implant removal is the cornerstone of treatment. For more advanced disease, treatment includes surgery followed by chemotherapy (combination anthracycline-based), radiotherapy and the antibody drug conjugate (brentuximab vedotin).

Summary

The interplay between the Gram-negative biofilm, implant texturing, genetic mutations and time has been implicated in pathogenesis of BIA-ALCL. The identification of a putative infectious cause is not unique to lymphomagenesis. Future research, investigating BIA-ALCL genetic mutations and immunological modulation with Gram-negative biofilm in BIA-ALCL models is warranted.
Literatur
1.
Barnsley GP, Sigurdson LJ, Barnsley SE. Textured surface breast implants in the prevention of capsular contracture among breast augmentation patients: a meta-analysis of randomized controlled trials. Plast Reconstr Surg. 2006;117(7):2182–2190.
2.
Wong CH, Samuel M, Tan BK, Song C. Capsular contracture in subglandular breast augmentation with textured versus smooth breast implants: a systematic review. Plast Reconstr Surg. 2006;118(5):1224–36.PubMedCrossRef
3.
Ajdic D, Zoghbi Y, Gerth D, Panthaki ZJ, Thaller S. The relationship of bacterial biofilms and capsular contracture in breast implants. Aesthet Surg J. Mar 2016;36(3):297–309.PubMedPubMedCentralCrossRef
4.
den Braber ET, de Ruijter JE, Smits HT, Ginsel LA, von Recum AF, Jansen JA. Effect of parallel surface microgrooves and surface energy on cell growth. J Biomed Mater Res. 1995;29(4):511–8.CrossRef
5.
Henderson PW, Nash D, Laskowski M, Grant RT. Objective comparison of commercially available breast implant devices. Aesthet Plast Surg. 2015;39(5):724–32.CrossRef
6.
Sforza M, Zaccheddu R, Alleruzzo A, et al. Preliminary 3-year evaluation of experience with SilkSurface and VelvetSurface motiva silicone breast implants: a single-center experience with 5813 consecutive breast augmentation cases. Aesthet Surg J. 2018;38(suppl_2):S62–73.PubMedCrossRef
7.
•• Hu H, Jacombs A, Vickery K, Merten SL, Pennington DG, Deva AK. Chronic biofilm infection in breast implants is associated with an increased T-cell lymphocytic infiltrate: implications for breast implant-associated lymphoma. Plast Reconstr Surg. 2015;135(2):319–29 This study identified the distinct microbiome in BIA-ALCL, identifying a possible infectious contributing cause. PubMedCrossRef
8.
Hu H, Johani K, Almatroudi A, Vickery K, van Natta B, Kadin ME, et al. Bacterial biofilm infection detected in breast implant-associated anaplastic large-cell lymphoma. Plast Reconstr Surg. 2016;137(6):1659–69.PubMedCrossRef
9.
Shahriari N, Ferenczi K, Heald PW. Breast implant-associated anaplastic large cell lymphoma: a review and assessment of cutaneous manifestations. Int J Womens Dermatol. 2017;3(3):140–4.PubMedPubMedCentralCrossRef
10.
Talwalkar SS, Miranda RN, Valbuena JR, Routbort MJ, Martin AW, Medeiros LJ. Lymphomas involving the breast: a study of 106 cases comparing localized and disseminated neoplasms. Am J Surg Pathol. 2008;32(9):1299–309.PubMedCrossRef
11.
Blombery P, Prince HM, Seymour JF. Primary breast lymphoma-population-level insights into an infrequent but increasingly recognized subtype of lymphoma. J Natl Cancer Inst. 2017;109(6).
12.
Hapgood G, Savage KJ. The biology and management of systemic anaplastic large cell lymphoma. Blood. 2015;126(1):17–25.PubMedCrossRef
13.
Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, et al. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project. Blood. Jun 15 2008;111(12):5496–504.PubMedCrossRef
14.
•• Clemens MW, Medeiros LJ, Butler CE, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34(2):160–8 This study proposed the “solid tumour” staging classifaction of BIA-ALCL and demonstrated the importance of complete surgical excision in the management of disease. PubMedCrossRef
15.
Clemens MW, Brody GS, Mahabir RC, Miranda RN. How to diagnose and treat breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2018;141:586e–98e.PubMedCrossRef
16.
Doren EL, Miranda RN, Selber JC, Garvey PB, Liu J, Medeiros LJ, et al. U.S. epidemiology of breast implant-associated anaplastic large cell lymphoma. Plast Reconstr Surg. 2017;139(5):1042–50.PubMedCrossRef
17.
•• Loch-Wilkinson A, Beath KJ, Knight RJW, et al. Breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand: high-surface-area textured implants are associated with increased risk. Plast Reconstr Surg. 2017;140(4):645–54 This study importantly proposed implant-specific risk for BIA-ALCL and reported the strong association between higher-surface-area textured implants and BIA-ALCL. PubMedCrossRef
18.
McGuire P. Reply: risk factor analysis for capsular contracture, malposition, and late seroma in subjects receiving natrelle 410 form-stable silicone breast implants. Plast Reconstr Surg. 2017;140(3):500e.PubMedCrossRef
19.
McGuire P, Reisman NR, Murphy DK. Risk factor analysis for capsular contracture, malposition, and late seroma in subjects receiving natrelle 410 form-stable silicone breast implants. Plast Reconstr Surg. Jan 2017;139(1):1–9.PubMedCrossRef
20.
Brody GS, Deapen D, Taylor CR, Pinter-Brown L, House-Lightner SR, Andersen JS, et al. Anaplastic large cell lymphoma occurring in women with breast implants: analysis of 173 cases. Plast Reconstr Surg. 2015;135(3):695–705.PubMedCrossRef
21.
Pennock ND, White JT, Cross EW, Cheney EE, Tamburini BA, Kedl RM. T cell responses: naive to memory and everything in between. Adv Physiol Educ. 2013;37(4):273–83.PubMedPubMedCentralCrossRef
22.
Turner S. An exploration into the origins and pathogenesis of anaplastic large cell lymphoma, anaplastic lymphoma kinase (ALK)-positive. Cancers 2017;9(141).
23.
Malcolm TI, Hodson DJ, Macintyre EA, Turner SD. Challenging perspectives on the cellular origins of lymphoma. Open Biol 2016;6(9).
24.
Lowe DB, Storkus WJ. Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy. 2011;3(10):1265–74.PubMedCrossRef
25.
Burg G, Kempf W, Haeffner A, et al. From inflammation to neoplasia: new concepts in the pathogenesis of cutaneous lymphomas. Recent Results Cancer Res. 2002;160:271–80.PubMedCrossRef
26.
Han A, Newell EW, Glanville J, et al. Dietary gluten triggers concomitant activation of CD4+ and CD8+ alphabeta T cells and gammadelta T cells in celiac disease. Proc Natl Acad Sci U S A. 2013;110(32):13073–8.PubMedPubMedCentralCrossRef
27.
Hardy MY, Tye-Din JA. Coeliac disease: a unique model for investigating broken tolerance in autoimmunity. Clin Transl Immunol. 2016;5(11):e112.CrossRef
28.
Lechner MG, Megiel C, Church CH, Angell TE, Russell SM, Sevell RB, et al. Survival signals and targets for therapy in breast implant-associated ALK--anaplastic large cell lymphoma. Clin Cancer Res. 2012;18(17):4549–59.PubMedCrossRef
29.
30.
Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest. 2007;117(12):3846–56.PubMedPubMedCentralCrossRef
31.
Kadin ME, Deva A, Xu H, Morgan J, Khare P, MacLeod RAF, et al. Biomarkers provide clues to early events in the pathogenesis of breast implant-associated anaplastic large cell lymphoma. Aesthet Surg J. 2016;36(7):773–81.PubMedCrossRef
32.
Wolfram D, Rabensteiner E, Grundtman C, Böck G, Mayerl C, Parson W, et al. T regulatory cells and TH17 cells in peri-silicone implant capsular fibrosis. Plast Reconstr Surg. 2012;129(2):327e–37e.PubMedCrossRef
33.
Fleury EF, Rego MM, Ramalho LC, et al. Silicone-induced granuloma of breast implant capsule (SIGBIC): similarities and differences with anaplastic large cell lymphoma (ALCL) and their differential diagnosis. Breast Cancer (Dove Med Press). 2017;9:133–40.
34.
Mazzocchi M, Dessy LA, Corrias F, Scuderi N. A clinical study of late seroma in breast implantation surgery. Aesthet Plast Surg. 2012;36(1):97–104.CrossRef
35.
Ravi-Kumar S, Sanaei O, Vasef M, Rabinowitz I, Fekrazad MH. Anaplastic large cell lymphoma associated with breast implants. World J Plast Surg. 2012;1(1):30–5.PubMedPubMedCentral
36.
Cappellano G, Ploner C, Lobenwein S, Sopper S, Hoertnagl P, Mayerl C, et al. Immunophenotypic characterization of human T cells after in vitro exposure to different silicone breast implant surfaces. PLoS One. 2018;13(2):e0192108.PubMedPubMedCentralCrossRef
37.
Mladick RA. Significance of Staphylococcus epidermidis causing subclinical infection. Plast Reconstr Surg. 2005;115(5):1426–7 author reply 1427–1428.PubMedCrossRef
38.
Clinton A, Carter T. Chronic wound biofilms: pathogenesis and potential therapies. Lab Med. 2015;46(4):277–84.PubMedCrossRef
39.
Myint AA, Lee W, Mun S, Ahn CH, Lee S, Yoon J. Influence of membrane surface properties on the behavior of initial bacterial adhesion and biofilm development onto nanofiltration membranes. Biofouling. 2010;26(3):313–21.PubMedCrossRef
40.
Teughels W, Van Assche N, Sliepen I, Quirynen M. Effect of material characteristics and/or surface topography on biofilm development. Clin Oral Implants Res. 2006;17(Suppl 2):68–81.PubMedCrossRef
41.
Jacombs A, Tahir S, Hu H, Deva AK, Almatroudi A, Wessels WLF, et al. In vitro and in vivo investigation of the influence of implant surface on the formation of bacterial biofilm in mammary implants. Plast Reconstr Surg. 2014;133(4):471e–80e.PubMedCrossRef
42.
Ryan MP, Adley CC. Ralstonia spp.: emerging global opportunistic pathogens. Eur J Clin Microbiol Infect Dis. 2014;33(3):291–304.PubMedCrossRef
43.
Pajkos A, Deva AK, Vickery K, Cope C, Chang L, Cossart YE. Detection of subclinical infection in significant breast implant capsules. Plast Reconstr Surg. 2003;111(5):1605–11.PubMedCrossRef
44.
Rieger UM, Mesina J, Kalbermatten DF, Haug M, Frey HP, Pico R, et al. Bacterial biofilms and capsular contracture in patients with breast implants. Br J Surg. 2013;100(6):768–74.PubMedCrossRef
45.
Schreml S, Heine N, Eisenmann-Klein M, Prantl L. Bacterial colonization is of major relevance for high-grade capsular contracture after augmentation mammaplasty. Ann Plast Surg. 2007;59(2):126–30.PubMedCrossRef
46.
Virden CP, Dobke MK, Stein P, Parsons CL, Frank DH. Subclinical infection of the silicone breast implant surface as a possible cause of capsular contracture. Aesthet Plast Surg. 1992;16(2):173–9.CrossRef
47.
Galdiero M, Larocca F, Iovene MR, Francesca M, Pieretti G, D’Oriano V, et al. Microbial evaluation in capsular contracture of breast implants. Plast Reconstr Surg. 2018;141(1):23–30.PubMedCrossRef
48.
Wang F, Meng W, Wang B, Qiao L. Helicobacter pylori-induced gastric inflammation and gastric cancer. Cancer Lett. 2014;345(2):196–202.PubMedCrossRef
49.
Wang MY, Liu XF, Gao XZ. Helicobacter pylori virulence factors in development of gastric carcinoma. Future Microbiol. 2015;10(9):1505–16.PubMedCrossRef
50.
Munford RS. Sensing gram-negative bacterial lipopolysaccharides: a human disease determinant? Infect Immun. 2008;76(2):454–65.PubMedCrossRef
51.
Jappe U. Superantigens and their association with dermatological inflammatory disease: facts and hypotheses. Acta Derm Venereol. 2000;20:321–8.CrossRef
52.
Irwin MJ, Hudson KR, Ames KT, Fraser JD, Gascoigne NR. T-cell receptor beta-chain binding to enterotoxin superantigens. Immunol Rev. 1993;131:61–78.PubMedCrossRef
53.
Kadin ME, Morgan J, Xu H, Glicksman CA. CD30+ T Cells in late seroma may not be diagnostic of breast implant-associated anaplastic large cell lymphoma. Aesthet Surg J. 2017;37(7):771–5.PubMedCrossRef
54.
Morrissey D, O'Sullivan GC, Tangney M. Tumour targeting with systemically administered bacteria. Curr Gene Ther. 2010;10(1):3–14.PubMedCrossRef
55.
Myckatyn TM, Parikh RP. Discussion: breast implant-associated anaplastic large cell lymphoma in Australia and New Zealand: high-surface-area textured implants are associated with increased risk. Plast Reconstr Surg. 2017;140(4):655–8.PubMedCrossRef
56.
Blombery P, Thompson ER, Jones K, Arnau GM, Lade S, Markham JF, et al. Whole exome sequencing reveals activating JAK1 and STAT3 mutations in breast implant-associated anaplastic large cell lymphoma anaplastic large cell lymphoma. Haematologica. 2016;101(9):e387–90.PubMedPubMedCentralCrossRef
57.
Crescenzo R, Abate F, Lasorsa E. Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. Cancer Cell. 2015;27(4):516–32.PubMedPubMedCentralCrossRef
58.
Di Napoli A, Jain P, Duranti E, et al. Targeted next generation sequencing of breast implant-associated anaplastic large cell lymphoma reveals mutations in JAK/STAT signalling pathway genes, TP53 and DNMT3A. Br J Haematol. 2018;180(5):741–4.PubMedCrossRef
59.
60.
Oishi N, Brody GS, Ketterling RP, Viswanatha DS, He R, Dasari S, et al. Genetic subtyping of breast implant-associated anaplastic large cell lymphoma. Blood. 2018;132:544–7.PubMedCrossRefPubMedCentral
61.
Pastorello RG, D'Almeida Costa F, Osorio C, et al. Breast implant-associated anaplastic large cell lymphoma in a Li-FRAUMENI patient: a case report. Diagn Pathol. 2018;13(1):10.PubMedPubMedCentralCrossRef
62.
Lee YS, Filie A, Arthur D, Fojo AT, Jaffe ES. Breast implant-associated anaplastic large cell lymphoma in a patient with Li-Fraumeni syndrome. Histopathology. 2015;67(6):925–7.PubMedPubMedCentralCrossRef
63.
Clemens MW, Horwitz SM. NCCN consensus guidelines for the diagnosis and management of breast implant-associated anaplastic large cell lymphoma. Aesthet Surg J. 2017;37(3):285–9.PubMedCrossRef
64.
Di Napoli A, Pepe G, Giarnieri E, et al. Cytological diagnostic features of late breast implant seromas: from reactive to anaplastic large cell lymphoma. PLoS One. 2017;12(7):e0181097.PubMedPubMedCentralCrossRef
65.
Alcala R, Llombart B, Lavernia J, Traves V, Guillen C, Sanmartin O. Skin involvement as the first manifestation of breast implant-associated anaplastic large cell lymphoma. J Cutan Pathol. 2016;43(7):602–8.PubMedCrossRef
66.
Kim B, Roth C, Chung KC, Young VL, van Busum K, Schnyer C, et al. Anaplastic large cell lymphoma and breast implants: a systematic review. Plast Reconstr Surg. 2011;127(6):2141–50.PubMedCrossRef
67.
Tardio JC, Granados R. Axillary lymphadenopathy: an outstanding presentation for breast implant-associated ALK-negative anaplastic large cell lymphoma. Int J Surg Pathol. 2015;23(5):424–8.PubMedCrossRef
68.
Cheson BD, Fisher RI, Barrington SF. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol. 2014;32(27):3059–68.PubMedPubMedCentralCrossRef
69.
Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, et al. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol. 2016;27(2):306–14.PubMedCrossRef
70.
Campanale A, Boldrini R, Marletta M. 22 cases of breast implant-associated ALCL: awareness and outcome tracking from the Italian Ministry of Health. Plast Reconstr Surg. 2018;141(1):11e–9e.PubMedCrossRef
71.
de Boer M, van Leeuwen FE, Hauptmann M, Overbeek LIH, de Boer JP, Hijmering NJ, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol. 2018;4(3):335–41.PubMedCrossRefPubMedCentral
72.
Clemens MW, Nava MB, Rocco N, Miranda RN. Understanding rare adverse sequelae of breast implants: anaplastic large-cell lymphoma, late seromas, and double capsules. Gland Surg. 2017;6(2):169–84.PubMedPubMedCentralCrossRef
73.
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130(25):2709–17.PubMedPubMedCentralCrossRef
Metadaten
Titel
Breast Implant-Associated Anaplastic Large Cell Lymphoma
verfasst von
P. Rastogi
A. K. Deva
H. Miles Prince
Publikationsdatum
22.10.2018
Verlag
Springer US
Erschienen in
Current Hematologic Malignancy Reports / Ausgabe 6/2018
Print ISSN: 1558-8211
Elektronische ISSN: 1558-822X
DOI
https://doi.org/10.1007/s11899-018-0478-2

Weitere Artikel der Ausgabe 6/2018

Current Hematologic Malignancy Reports 6/2018 Zur Ausgabe

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Social Media and Hematopoietic Cell Transplantation: a Review of Online Resources and Communities

Molecular Testing and Diagnostics (J Khoury, Section Editor)

Blastic Plasmacytoid Dendritic Cell Neoplasm

Molecular Testing and Diagnostics (J Khoury, Section Editor)

Recent Updates on Chronic Myelomonocytic Leukemia

Social Media Impact of Hematologic Malignancies (N Pemmaraju, Section Editor)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) on Social Media: #BPDCN—Increasing Exposure over Two Years Since Inception of a Disease-Specific Twitter Community

Myelodysplastic Syndromes (M Savona, Section Editor)

Leveraging Hypomethylating Agents for Better MDS Therapy

B-cell NHL, T-cell NHL, and Hodgkin Lymphoma (J Amengual, Section Editor)

Anti-CD19 Chimeric Antigen Receptor T Cell Therapies: Harnessing the Power of the Immune System to Fight Diffuse Large B Cell Lymphoma

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 | NSCLC | Nachrichten

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

24.04.2024 | DGIM 2024 | Nachrichten

Bei Senioren mit Prostatakarzinom auf Anämie achten!

23.04.2024 | Medikamente in Schwangerschaft und Stillzeit | Nachrichten

ICI-Therapie in der Schwangerschaft wird gut toleriert
weitere anzeigen

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen